2021 Volume 57 Issue 2 Pages 376-380
The expansion of the treatment indications of everolimus for neonatal tuberous sclerosis complex（TSC）has been approved, with its effectiveness toward the cardiac rhabdomyoma being continuously reported. However, many of the issues related to its usage have not been fully resolved. We encountered a case of TSC with cardiac rhabdomyoma in a 2,488 g low-birth-weight preterm infant born through emergency cesarean section at 35 weeks and 5 days of gestation owing to a cardiac tumor discovered during the fetal period. This tumor located in the interventricular septum and the tumor was enlarged postnatally. The administration of everolimus was commenced, considering the risk of right ventricular outflow tract stenosis. Shrinkage was confirmed at 50 days old with no adverse reaction. In December 2019, expert opinion consensus for everolimus treatment was given for emergencies caused by neonatal cardiac rhabdomyoma in TSC. However, there are only few reports of therapeutic intervention for preterm infants. Based on the course of this case, we consider the appropriate treatment for the cardiac rhabdomyoma in the preterm infant and report it here.
